Patrick W. Smith Sells 4,767 Shares of Axon Enterprise, Inc. (NASDAQ:AXON) Stock

Axon Enterprise, Inc. (NASDAQ:AXON) CEO Patrick W. Smith sold 4,767 shares of the firm’s stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $404.14, for a total transaction of $1,926,535.38. Following the transaction, the chief executive officer now directly owns 2,925,060 shares in the company, valued at approximately $1,182,133,748.40. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Axon Enterprise Price Performance

NASDAQ:AXON traded up $6.75 on Friday, hitting $421.80. The company had a trading volume of 611,871 shares, compared to its average volume of 524,369. Axon Enterprise, Inc. has a 52 week low of $192.63 and a 52 week high of $422.33. The company has a current ratio of 2.88, a quick ratio of 2.52 and a debt-to-equity ratio of 0.35. The stock has a market capitalization of $31.83 billion, a price-to-earnings ratio of 123.33, a PEG ratio of 10.59 and a beta of 0.94. The firm has a 50 day moving average of $363.44 and a two-hundred day moving average of $322.68.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.18. The company had revenue of $504.00 million during the quarter, compared to analysts’ expectations of $478.35 million. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. Axon Enterprise’s revenue was up 34.5% compared to the same quarter last year. During the same period in the prior year, the company earned $0.80 EPS. On average, research analysts anticipate that Axon Enterprise, Inc. will post 1.79 earnings per share for the current year.

Analyst Upgrades and Downgrades

AXON has been the topic of several recent research reports. Robert W. Baird raised their target price on shares of Axon Enterprise from $360.00 to $400.00 and gave the stock an “outperform” rating in a report on Tuesday, September 10th. Northland Securities lifted their price objective on Axon Enterprise from $330.00 to $365.00 and gave the company an “outperform” rating in a report on Thursday, August 8th. Bank of America initiated coverage on Axon Enterprise in a report on Wednesday, July 17th. They set a “buy” rating and a $380.00 target price on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $400.00 price target on shares of Axon Enterprise in a research note on Wednesday, August 7th. Finally, JMP Securities increased their price objective on shares of Axon Enterprise from $375.00 to $430.00 and gave the stock an “outperform” rating in a research note on Thursday, September 12th. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $365.38.

Institutional Trading of Axon Enterprise

Several hedge funds and other institutional investors have recently made changes to their positions in AXON. Vanguard Group Inc. increased its holdings in Axon Enterprise by 2.7% in the first quarter. Vanguard Group Inc. now owns 8,143,306 shares of the biotechnology company’s stock valued at $2,547,878,000 after purchasing an additional 212,401 shares during the period. Motley Fool Asset Management LLC increased its stake in shares of Axon Enterprise by 238.7% in the first quarter. Motley Fool Asset Management LLC now owns 492,140 shares of the biotechnology company’s stock valued at $153,981,000 after buying an additional 346,838 shares during the period. 1832 Asset Management L.P. raised its position in shares of Axon Enterprise by 44.0% during the second quarter. 1832 Asset Management L.P. now owns 375,700 shares of the biotechnology company’s stock worth $110,546,000 after acquiring an additional 114,800 shares during the last quarter. Allspring Global Investments Holdings LLC raised its position in shares of Axon Enterprise by 13.9% during the second quarter. Allspring Global Investments Holdings LLC now owns 368,732 shares of the biotechnology company’s stock worth $108,496,000 after acquiring an additional 45,049 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in Axon Enterprise by 110.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 276,011 shares of the biotechnology company’s stock valued at $71,302,000 after acquiring an additional 144,568 shares during the last quarter. 79.08% of the stock is currently owned by institutional investors.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.